Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial
| dc.contributor.author | Gleeson, M. | |
| dc.contributor.author | Counsell, N. | |
| dc.contributor.author | Cunningham, D. | |
| dc.contributor.author | Lawrie, A. | |
| dc.contributor.author | Clifton-Hadley, L. | |
| dc.contributor.author | Hawkes, E. | |
| dc.contributor.author | McMillan, A. | |
| dc.contributor.author | Ardeshna, K. M. | |
| dc.contributor.author | Burton, C. | |
| dc.contributor.author | Chadwick, N. | |
| dc.contributor.author | Gambell, J. | |
| dc.contributor.author | Smith, P. | |
| dc.contributor.author | Mouncey, P. | |
| dc.contributor.author | Pocock, C. | |
| dc.contributor.author | Radford, John A | |
| dc.contributor.author | Davies, J. | |
| dc.contributor.author | Turner, D. | |
| dc.contributor.author | Kruger, A. | |
| dc.contributor.author | Johnson, P. | |
| dc.contributor.author | Linch, D. | |
| dc.date.accessioned | 2020-06-16T11:03:14Z | |
| dc.date.available | 2020-06-16T11:03:14Z | |
| dc.date.issued | 2020 | en |
| dc.identifier.citation | M. Gleeson, N. Counsell, D. Cunningham et al. Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial. Br J Haematol. 2020. | en |
| dc.identifier.pmid | 32436212 | en |
| dc.identifier.doi | 10.1111/bjh.16691 | en |
| dc.identifier.uri | http://hdl.handle.net/10541/623025 | |
| dc.description.abstract | We compared the International Prognostic Index (IPI), Revised (R)-IPI and age-adjusted (aa)-IPI as prognostic indices for patients with diffuse large B-cell lymphoma (DLBCL) in the UK National Cancer Research Institute (NCRI) R-CHOP 14 versus 21 trial (N = 1080). The R-IPI and aa-IPI showed no marked improvement compared to the IPI for overall and progression-free survival, in terms of model fit or discrimination. Similar results were observed in exploratory analyses incorporating the Grupo Espanol de Linfomas/Transplante de Medula Osea (GELTAMO)-IPI, where baseline beta2-microglobulin data were available (N = 655). Although our findings support current use of the IPI, a novel prognostic tool to better delineate a high-risk DLBCL group in the rituximab era is needed. | en |
| dc.language.iso | en | en |
| dc.relation.url | https://dx.doi.org/10.1111/bjh.16691 | en |
| dc.title | Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial | en |
| dc.type | Article | en |
| dc.contributor.department | The Royal Marsden Hospital, London and Surrey, London, UK. | en |
| dc.identifier.journal | British Journal of Haematology | en |
| dc.description.note | en] |